Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know

Nat Rev Clin Oncol. 2011 Aug 2;8(10):577-85. doi: 10.1038/nrclinonc.2011.116.


Cancer immunotherapy using the adoptive transfer of autologous tumor-infiltrating lymphocytes results in objective cancer regression in 49-72% of patients with metastatic melanoma. In a pilot trial combining cell transfer with a maximum lymphodepleting regimen, complete durable responses were seen in 40% of patients, with complete responses ongoing beyond 3 to 7 years. Current approaches to cell transfer therapy using autologous cells genetically engineered to express conventional or chimeric T-cell receptors have mediated cancer regression in patients with metastatic melanoma, synovial sarcoma, neuroblastoma and refractory lymphoma. Adoptive cell transfer immunotherapy is a rapidly developing new approach to the therapy of metastatic cancer in humans. This Review will emphasize the current available applications of cell transfer immunotherapy for patients with cancer.

Publication types

  • Review

MeSH terms

  • Adoptive Transfer
  • Humans
  • Immunotherapy*
  • Lymphocytes, Tumor-Infiltrating / immunology*
  • Neoplasm Metastasis
  • Neoplasms / immunology
  • Neoplasms / pathology*
  • Neoplasms / therapy*
  • T-Lymphocytes / cytology
  • T-Lymphocytes / transplantation*